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Abstract: Retroviruses are RNA viruses that replicate through a DNA intermediate, in a 
process catalyzed by the viral reverse transcriptase (RT). Although cellular polymerases 
and host factors contribute to retroviral mutagenesis, the RT errors play a major role in 
retroviral mutation. RT mutations that affect the accuracy of the viral polymerase have 
been identified by in vitro analysis of the fidelity of DNA synthesis, by using 
enzymological (gel-based) and genetic assays (e.g., M13mp2 lacZ forward mutation 
assays). For several amino acid substitutions, these observations have been confirmed in 
cell culture using viral vectors. This review provides an update on studies leading to the 
identification of the major components of the fidelity center in retroviral RTs. 
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1. Introduction  
Virulence, pathogenesis and the ability to develop effective antiretroviral drugs and vaccines are 
largely dependent on retroviral variation. Genetic diversity in retroviruses has been widely 
documented, particularly in the case of human immunodeficiency virus type 1 (HIV-1) and simian 
immunodeficiency virus (SIV) [1-3]. Genetic variation in HIV-1 has been estimated from nucleotide 
sequence analysis of sequential isolates taken from individuals infected with a known viral source. 
Mutation rates of 10
-3 and 10
-4 nucleotide substitutions per site per year have been obtained for the 
HIV-1 env and gag genes, respectively.  
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Several methods have been used to determine the mutation rates of retroviruses in tissue culture 
(i.e., the mutation frequency in a single cycle of retroviral replication). These methods imply the use of 
a vector virus genome which contains a target gene for scoring mutations [for a review, see Ref. 4]. 
Examples of genes that have been used as mutation reporters are lacZ or its truncated peptide (lacZα), 
the neomycin phosphotransferase gene (neo), the herpes thymidine kinase gene and the green 
fluorescent protein gene. The retroviral vector encoding the reporter gene is introduced into a 
packaging cell line and the virus produced is used to infect target cells lacking the gag-pol-env genes. 
The vector can complete one round of replication and integrate in the target cell genome to form a 
provirus. However, because the vector is unable to express any viral proteins, additional cycles of 
replication cannot occur. At this point, an appropriate selection of cultured cells can determine the 
wild-type or mutant phenotype of the target gene and mutant frequencies can be obtained.  
Mutation rates based on the inactivation of the reporter gene have been determined for several 
retroviruses, such as spleen necrosis virus (SNV), Rous sarcoma virus (RSV), murine leukemia virus 
(MLV), bovine leukemia virus (BLV), HIV-1 and human T-cell leukemia virus I (HTLV-I), and range 
from 2 x 10
-5 to 6 x 10
-6 per nucleotide per replication cycle [5-16]. The large differences obtained 
could be attributed in part to the different vectors and packaging and target cells used in these 
experiments. For example, reported estimates of the mutation rate of MLV ranged from 2 x 10
-6 [8] to 
2 x 10
-5 [7]. Nevertheless, these values are well above the values reported for DNA-based microbes 
which range from 10
-7 to 10
-11 [17; for a review, see Ref. 18]. 
Retroviruses are RNA viruses that replicate through a DNA intermediate. Retroviral polymerases 
[i.e., reverse transcriptases (RTs)] are multifunctional enzymes possessing RNA- and DNA-dependent 
DNA polymerase, RNase H, strand transfer and strand displacement activities but devoid of 3´5´ 
exonuclease activity [reviewed in Refs. 19,20]. The double-stranded DNA resulting from reverse 
transcription is integrated into the host cell genome, where it is stably maintained as a provirus. 
Cellular DNA polymerases are responsible for the replication of the integrated viral DNA. Cellular 
RNA polymerase II transcribes the proviral DNA into RNA genomes that are packaged into virions. 
Unlike cellular DNA polymerases, viral RTs are devoid of 3´5´ exonucleolytic proofreading 
activity. Average base substitution error rates for proofreading-proficient DNA polymerases   
(i.e., DNA polymerases δ, γ, and/or ε) are about 10
-6 to 10
-7 [21,22], and 10 – 100 times lower than 
those of retroviral RTs. Based on those studies, it has been assumed that retroviral variation is largely a 
result of errors made by RT, although cellular RNA polymerase II as well as viral and host factors do 
have an effect on the retroviral mutation rate. In this review, we will discuss on different mechanisms 
influencing retroviral mutation rate with an emphasis on recent developments towards understanding 
the relationship between RT structure and its fidelity of DNA synthesis. 
2. Viral and Host Factors Influencing Retroviral Mutation Rate 
The cellular transcriptional machinery, physiological fluctuations of dNTP pools and asymmetric 
error repair contribute to viral variation in the host cell (Figure 1). The contribution of the cellular 
RNA polymerase II is real but largely unknown. Early observations on the fidelity of wheat-germ 
RNA polymerase II in vitro that ranged from one error every 250 to one error in every 200,000 
nucleotides polymerized, depending on the mutation type and on the sequence and structure of the Viruses 2009, 1                  
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template [23] suggested that RNA transcription was relatively error prone and contributed to retroviral 
mutagenesis.  
Figure 1. Major steps of the retroviral replication cycle and host factors that could 
influence the viral mutation rate. 
 
 
Enzymatic studies carried out in vitro with DNA-dependent RNA polymerases revealed that 
misincorporation leads to slow addition of the next nucleotide, whereas a mismatched RNA 3´ end can 
be removed with factors that stimulate the polymerase cleavage activity (e.g., Gre A in E. coli, or 
TFIIS in human cells) [24,25]. Recent reports have also demonstrated that transcriptional fidelity and 
proofreading do not require cleavage-stimulatory factors, but are intrinsic properties of RNA 
polymerases [26; reviewed in Ref. 27]. Sydrow et al. [28] have shown that RNA polymerase II 
evolved mismatch-specific fidelity mechanisms. Thus, certain DNA/RNA mismatches are efficiently 
formed, but impair RNA extension (e.g., A:C, C:U, etc.), while others allow for RNA extension but are 
inefficiently formed and efficiently proofread by RNA cleavage (e.g., G:G) [28]. X-ray analysis 
revealed that a T:U mismatch impairs RNA extension by forming a wobble base pair at the RNA 
polymerase II active site that dissociates the catalytic metal ion and misaligns the RNA 3´ end. On the 
other hand, an error rate as low as 1.9 x 10
-7 to 2.3 x 10
-7 mutations per copied nucleotide has been 
determined for the yellow fever virus RNA-dependent RNA polymerase [29], a value which is well 
above the generally accepted mutation rates for viral RNA polymerases of 10
-4 to 10
-5. 
The relative contributions of viral RT and host cell RNA polymerase II to the high rate of HIV-1 
mutation have been evaluated in a single cycle of virus replication, through the mutational analysis of Viruses 2009, 1                  
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HIV-1 long terminal repeats (LTRs). After sequencing 215 proviruses, O’Neil et al. found 21 
independent mutations, 10 of them in both LTRs and 11 of them in only one of the LTRs [30]. In their 
experimental design, mutations found in both LTRs could have been introduced by either the RT or the 
RNA polymerase II, while the 11 mutations found in one of the LTRs could only have been introduced 
by the HIV-1 RT. These results provided direct evidence of the larger contribution of the RT to HIV-1 
mutagenesis.  
The RT is not the only viral protein that influences the retroviral mutation rate. Several retroviruses 
[e.g., feline immunodeficiency virus (FIV), equine infectious anemia virus (EIAV), mouse mammary 
tumor virus (MMTV) and Mason-Pfizer monkey virus (MPMV)] encode a dUTP pyrophosphatase 
(dUTPase) [31,32]. Retroviral dUTPases reduce mutation levels by preventing the incorporation of 
uracil into the viral genome and therefore safeguarding efficient reverse transcription [33]. On the 
other hand, accessory proteins such as Vpr in HIV-1 have been shown to contribute to the accuracy of 
reverse transcription in single-cycle replication assays using the lacZα gene as a mutational target. The 
mutation rate of a vpr
– vector mutant was about 4 times higher than that of the vpr
+ parental vector 
(estimated at 3.4 x 10
-5 per nucleotide and replication cycle), supporting the conclusion that the vpr 
gene partially accounts for the lower than predicted in vivo mutation rate of HIV-1 [11,34].  
Vpr is a highly conserved regulatory protein of 96 residues that contains a central hydrophobic core 
domain with three α-helices surrounded by flexible N- and C-terminal domains [35]. Vpr is 
incorporated into virions and contributes both to reverse transcription and to the nuclear import of the 
HIV-1 preintegration complex [for recent reviews, see Refs. 36,37]. Vpr has been found to recruit the 
nuclear form of uracil DNA glycosylase (UNG2) into HIV-1 virions [38,39]. Replacement of Trp54 by 
Arg in Vpr is sufficient to disrupt its binding to UNG [39,40]. UNG is a key component of DNA repair 
mechanisms either in the nucleus or in the mitochondria, through the involvement of specific isoforms 
(UNG2 and UNG1, respectively) [41]. Although earlier reports indicated that Vpr-mediated 
incorporation of UNG2 into HIV-1 virions was required to modulate the virus mutation rate [39,42], 
recent reports suggest that UNG2 encapsidation has a detrimental effect on virus replication [43]. 
Although the later model proposes that Vpr induces proteasomal degradation of UNG2 in virus-
producing cells, others have demonstrated that the Vpr-induced reduction of UNG2 levels in infected 
cells could be related to a negative transcriptional effect on UNG2 expression [44].  
In addition, Vpr-independent packaging of UNG2 into HIV-1 virions has also been demonstrated 
[45]. This process appears to be mediated by the specific association between UNG2 and the integrase 
domain of the Gag-Pol precursor, and involves Leu172 in the viral integrase [46]. 
Apolipoprotein B mRNA-editing, catalytic polypeptide-like enzymes (APOBEC3) are cytidine 
deaminases that cause hypermutations of nascent retroviral genomes by deamination of cytidine 
residues [for recent reviews, see Refs. 47,48]. In the absence of the HIV-1 viral infectivity factor (Vif) 
protein, human APOBEC3G and APOBEC3F are encapsidated into budding virions. When these viral 
particles infect new target cells, two effects are observed: (i) the nascent viral reverse transcripts 
appear to be extensively mutated [49-51], and (ii) there is a significant reduction in the amount of viral 
DNA that accumulates in cells, due either to an inhibitory effect of APOBEC proteins on cDNA 
synthesis, or to an increase degradation of reverse transcripts [50,52-54; and references therein]. The 
proposal linking hypermutation to DNA degradation due to the UNG-mediated formation of abasic 
sites susceptible to degradation by cellular apurinic/apyrimidinic endonucleases [49,50] has been Viruses 2009, 1                  
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challenged by reports showing that various APOBEC proteins are able to inhibit MMTV or 
retrotransposons, with little or no detectable editing activity [55-57; reviewed in Ref. 58]. The virally 
encoded Vif protein allows HIV to overcome the activity of APOBEC proteins, resulting in a non-
lethal level of GA mutations. This proposal raises the intriguing possibility that these innate factors 
may directly shape the evolutionary diversity of retroviruses.  
The contribution of other viral and cellular factors is still uncertain. The viral nucleocapsid protein 
(NC) could enhance the rate of viral DNA synthesis in regions of the template containing secondary 
structure [59], and biochemical studies have shown differences in the ability of the MLV RT to extend 
different mutated primers using RNA or DNA templates [60]. In addition, the nucleic acid chaperone 
activity of NC appears to play a key role in the selection of the 3´ polypurine tract (PPT) required for 
plus-strand DNA synthesis [61], and thereby safeguarding fidelity at this step of reverse transcription. 
In addition, cellular enzymes modifying nucleic acids (including host DNA repair enzymes) could 
potentially affect the retroviral mutation rate. Among them, the tumor suppressor protein p53 displays 
3´5´ exonuclease activity, and shows a preference for mispaired 3´ termini. In specific cell types, 
p53 could facilitate the extension of correctly paired 3´-terminus by HIV-1 RT [62,63].  
3. Intrinsic Fidelity of Retroviral RTs: M13mp2 lacZ Forward Mutation Assays 
The intrinsic fidelity of purified retroviral RTs can be analyzed in vitro by using enzymological 
(gel-based) or genetic assays [for an extensive review, see Ref. 64]. Gel-based assays include dNTP 
exclusion assays as well as determinations of kinetic constants (i.e.,  kpol and Kd values, under   
pre-steady-state conditions) for the incorporation of correct or incorrect nucleotides on matched and 
mismatched template-primers. The dNTP exclusion assays are usually performed in the presence of 
three dNTPs, each one at a relatively high concentration, and provide a rough estimate of fidelity 
based on the observed primer extension efficiencies. In contrast, kinetic experiments   
(i.e., misinsertion and mispair extension fidelity assays) provide detailed mechanistic insight on the 
processes governing the accuracy of DNA synthesis. However, these assays are time-consuming and 
usually restricted to the analysis of a small number of incorporation sites.  
Genetic assays include the determination of the forward mutation rate of a reporter gene or the 
reversion of a nonsense codon. Forward mutation assays allow the exploration of a wide variety of 
sequence contexts that may help the identification of relevant hot spots related to reverse transcription 
errors. These assays provide information not only on single-nucleotide substitutions, but also on 
frameshifts and small deletions and insertions within the target gene. Silent mutations are not detected. 
However, forward mutation assays score for phenotypically detectable nucleotide changes at many 
different sites and in different sequence contexts, thereby providing a fidelity assessment based on a 
relatively large number of mutational target sites.  
Mutation rates of purified RTs have been frequently determined with a forward mutation assay in 
which the lacZα gene serves as a mutation reporter. In this assay, the substrate is a gapped double-
stranded M13mp2 DNA duplex, where the lacZ sequence of one of the DNA strands has been deleted. 
Gap-filling reactions are carried out in the presence of RT and relatively high concentrations of all four 
dNTPs. Mutants are identified after transformation of appropriate bacteria by the white/blue color of 
M13 plaques revealed using X-Gal indicator plates [for a detailed description of the procedure, see Viruses 2009, 1                  
 
 
1142
Ref. 65]. Other reporter genes used in this type of assays are the HIV-1 env gene variable region 1 
(V1) (cloned in M13) [66] or lacZ (cloned in vectors pBluescript or Litmus 29) [67,68]. Estimated 
error rates for retroviral RTs using forward mutation assays are given in Table 1.  
Table 1. Estimated error rates of retroviral RTs, as determined by using forward mutation assays. 
Enzyme  Vector and reporter gene  Template Error rate  References 
HIV-1 RT 
(group M subtype B) 
M13mp2, lacZα  DNA  0.6 – 6.7 x 10
-4 [69-79] 
 pBluescript,  lacZ  DNA  1.7 x 10
-4 [67] 
 pBluescript,  lacZ  RNA  1.4 x 10
-4 [67] 
 M13,  env V1  DNA  1.9 x 10
-4 [66] 
 M13,  env V1  RNA  2.0 x 10
-4 [66] 
  Litmus 29 (uracil-containing 
DNA), lacZ 
DNA  0.75 – 1.6 x 10
-4 [68,80] 
HIV-1 RT 
(group O) 
M13mp2, lacZα  DNA  5.5 x 10
-5 [79] 
SIVagm RT  M13mp2, lacZα  DNA  2.9 x 10
-5 [81] 
SIVmne RT  M13mp2, lacZα DNA  1.2 x 10
-4 (CL8) 
a 
1.6 x 10
-5 (170) 
[82] 
PFV RT  Litmus 29, lacZ  DNA  1.7 x 10
-4 [80] 
FIV RT  M13mp2, lacZα  DNA  6.2 x 10
-5 [83] 
AMV RT  M13mp2, lacZα  DNA  5.9 x 10
-5 [69,84] 
Mo-MLV RT  M13mp2, lacZα  DNA  3.3 x 10
-5 [69,84] 
 pBluescript,  lacZ  DNA  3.4 x 10
-5 [67] 
 pBluescript,  lacZ  RNA  2.7 x 10
-5 [67] 
FeLV RT  M13mp2, lacZα  DNA  5.8 x 10
-6 [83] 
a CL8 and 170 are strains of SIVmne that infected the same pig-tailed macaque. The 170 strain is a representative 
clone of the late symptomatic phase of the infection.  
 
Reported error rates for HIV-1 RT show a large variability that appears to originate in the gap-
filling reaction, since differences are already detected while counting the number of mutant plaques. 
Another source of uncertainty is that the equivalence between mutant frequencies (white/pale blue 
versus blue plaques) and error rates is not straightforward, since detectable mutations and frameshifts 
do not occur with the same frequency at all sites, and sometimes, authors made their calculations based 
on partial sequences of the reporter genes. In addition, the observed variations could be explained in 
part by the different wild-type HIV-1 RTs used in these experiments [i.e., homodimers (p66/p66) 
versus heterodimers (p66/p51), or RT variants derived from different viral strains, such NL4-3, HXB2, 
BH10 or NY5]. Forward mutation assays carried out under the same conditions revealed that HIV-1 
RT was around 10 times less accurate than the AMV RT and 20 times less accurate than the Moloney 
MLV (Mo-MLV) RT [69,70,84]. In general, lentiviral RTs appear to be more error prone than 
oncoretroviral RTs. Thus, in M13mp2 lacZ forward mutation assays, feline leukemia virus (FeLV) RT Viruses 2009, 1                  
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was found to be approximately 11 times more faithful than feline immunodeficiency virus (FIV) RT 
[83].  
SNV, MLV and HIV-1 RTs induce a similar broad spectrum of mutations during reverse 
transcription in vivo [6,11,85]. Most of them are substitution mutations. Transitions account for about 
80% of the total number of mutations, whereas GA transitions are the most frequent base 
substitutions. The comparison of the mutational spectra of HIV-1 and AMV RTs obtained in vitro 
using forward mutation assays revealed that HIV-1 RT shows a much higher error rate for frameshifts 
than the AMV RT (2.3 x 10
-4 versus 1.0 x 10
-5) [70,84]. Most of the frameshifts generated by HIV-1 
RT appear at homopolymeric runs and could be explained by invoking a misalignment/slippage 
mechanism [70,86] (Figure 2).  
Figure 2. Proposed models and mutational intermediates leading to the generation of base 
substitutions and frameshift errors [adapted from Ref. 86].  
 
 
Forward mutation assays carried out with RTs derived from the HIV-1 group M subtype B clade 
and from a phylogenetically distant group O isolate [87,88] demonstrated that the wild-type HIV-1 Viruses 2009, 1                  
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group O RT shows a very low frameshift fidelity in comparison with the subtype B enzyme [79]. 
During DNA synthesis, both highly divergent RTs are capable of generating substitution errors at 
specific sites at extraordinarily high rates (10
-2 to 10
-3) [69,70,79,81]. These hot spots are located at the 
boundaries of homopolymeric nucleotide runs. This location, together with the observed substitution 
specificity (mostly TC and GA mutations, derived from T:dGTP and G:dTTP mispairs) suggest 
that the hot spots result from a dislocation mechanism (Figure 2). This model assumes that the base 
substitution error is initiated at the end of a run by template-primer slippage. However, the formation 
of several mutational hot spots generated by HIV-1 RT when copying uracil-containing DNA 
templates could not be explained by dislocation mutagenesis, suggesting that direct misinsertion of the 
incorrect base is also an important contributor towards mutagenesis [80]. 
The comparison of mutational spectra of HIV-1 RT and other retroviral RTs revealed similar 
patterns for other closely-related lentiviral RTs, such as SIVagm RT [81], whereas AMV RT and the 
prototype foamy virus (PFV) RT did not appear to make errors at specific spots [80,84]. PFV RT had 
similar error rates for single nucleotide substitutions, but made more deletions and insertions than the 
HIV-1 RT [80]. However, the analysis of mutations after a single round of reverse transcription using a 
replication-deficient vector system revealed that the replication of the foamy virus genome is more 
accurate than previously thought, while the proportion of deletions and insertions was almost 
negligible [89]. The discrepancies between the results obtained with PFV RT and the viral vector has 
been attributed in part to the viral Bet protein that could interact with members of the APOBEC 
family. 
Fidelity of retroviral RTs copying RNA in vitro 
Forward mutation assays have been adapted for estimating the error rate of retroviral RTs while 
copying RNA versus DNA templates. The results obtained have been diverse, probably as a 
consequence of the different templates used in the DNA synthesis reaction. Using the M13mp2 lacZα 
forward mutation assay, Boyer et al. [71] showed that the fidelity of HIV-1 RT was several-fold higher 
with RNA than with DNA. The largest differences were observed for single nucleotide substitutions 
and –1 frameshifts at homopolymeric runs suggesting that misaligned intermediates are formed or used 
less frequently with an RNA template-DNA primer than with a DNA template-DNA primer. Using a 
modified ΦX174 amber codon reversion assay, Hübner et al. [90] reported that the error rates for 
U:dGTP and rA:dGTP with HIV-1 RT were 20-fold and 7-fold higher, respectively, than the rates for 
the corresponding errors with a DNA template and the same sequence. In contrast, the base 
substitution fidelity of HIV-1 RT for errors likely to result from direct miscoding was found to be 
similar on RNA and DNA templates of the same sequence [66,67,71]. These results were consistent 
with the relatively small differences (about 2-fold) in mutation rates determined for RNA- and DNA-
dependent DNA synthesis in vivo [91]. HIV-1 RT was also found to be less accurate than MLV RT 
[67] and AMV RT [71], demonstrating that error rates on RNA template are enzyme-dependent, as for 
DNA templates. Viruses 2009, 1                  
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4. Assessing Fidelity of DNA Synthesis Using Nucleotide Incorporation Kinetics 
Nucleotide selectivities based on the determination of kinetic parameters for the incorporation of 
correct and incorrect nucleotides on specific template-primers provide a valuable estimate of the 
fidelity of DNA synthesis [reviewed in Refs. 64,92,93]. In misinsertion fidelity assays, a binary 
complex is formed between the RT and the template-primer. Then, the ability to extend the primer in 
the presence of the correct or incorrect nucleotide is determined. The efficiency of nucleotide 
incorporation is measured by quantitative gel electrophoresis, and the data are analyzed to obtain 
kinetic parameters by using the Michaelis-Menten equation. The kinetic parameters kcat and Km can be 
determined under steady-state conditions. However, steady-state kinetic constants are not appropriate 
to obtain mechanistic insight into the DNA polymerization reaction, since the kcat and Km values are 
strongly influenced by the slow rate of dissociation of the template-primer from the enzyme (koff). 
In contrast, pre-steady-state kinetic parameters obtained under conditions where the DNA 
concentration is in slight excess relative to the RT concentration provide a much better assessment of 
the nucleotide incorporation rate and the dNTP binding affinity. Rapid transient kinetics allow the 
determination of kinetics of nucleotide incorporation after time intervals ranging from 3 ms to several 
seconds, and therefore the measurement of the equilibrium dissociation constant (Kd) for the 
interaction of dNTP and the RT/template-primer complex, as well as the reaction turnover (kpol). 
Nucleotide selectivity (e.g., misinsertion ratio) can be estimated from the ratio between the kpol/Kd 
values for incorporation of incorrect and correct base pairs. 
For retroviral RTs (e.g., HIV-1 RT, MLV RT or SIV RT), the misinsertion fidelity of DNA-directed 
DNA synthesis is determined by a 10- to 100-fold reduction in the affinity for non-complementary 
dNTPs, and a 10- to 10,000-fold reduction in the rate of conformational change that limits the rate of 
nucleotide addition [94,95]. Reported misinsertion ratios are within the range of 10
-3 to 10
-6 and are 
lower for purine:purine and pyrimidine:pyrimidine base pairs [76,78,79,82,95-98]. 
The events leading to the fixation of a mutation involve nucleotide misincorporation, followed by 
extension of a mispaired template-primer. Efficient extension of mismatched 3´ termini is a major 
determinant of the low fidelity of HIV-1 and other retroviral RTs [99]. Extension of mispaired primer 
termini proceed at a rate one to three orders of magnitude faster than the dissociation of the retroviral 
RT from DNA, providing a mechanism for fixation of misincorporated nucleotides [95]. Mispair 
extension assays involve the determination of kinetic constants (kpol and Kd) for the incorporation of a 
correct nucleotide, using template-primers with matched or mismatched 3´ termini. Reported mispair 
extension efficiencies for MLV and HIV-1 RTs are usually within the range of 10
-2 to 10
-4. The highest 
mispair extension efficiencies are usually obtained for G:T or T:G mispairs [78,79]. Studies with 
RNA-DNA and DNA-DNA template-primers, bearing the same nucleotide sequences (except for the 
presence of U instead of T in the RNA template), showed that copying fidelity was around 10-25 times 
more accurate with the RNA template [96]. However, the number of sequence contexts analyzed in 
those studies was relatively small. 
Despite the limitations of the steady-state kinetics approach, it should be noted that reported 
misinsertion and mispair extension ratios obtained under steady-state conditions were broadly similar 
to those calculated from pre-steady-state kinetic measurements. Steady-state misinsertion and mispair 
extension efficiencies were usually higher for HIV-1 RT and other lentiviral RTs [e.g., HIV-2, SIV, Viruses 2009, 1                  
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EIAV, FIV, and bovine immunodeficiency virus (BIV) RTs] than for MLV, FeLV and AMV RTs, in 
agreement with the results obtained using forward mutation assays [83,100-104]. Bovine leukemia 
virus (BLV) RT showed higher misinsertion fidelity than HIV-1 RT but lower than that of MLV RT, 
although the patterns of mispair elongation by the BLV enzyme suggested that its fidelity was similar 
to that reported for HIV-1 RT [105]. The MMTV RT was about 2- to 4-fold more error prone than 
AMV RT in misinsertion assays and showed a higher ability to extend mismatched template-primers 
[106]. On the other hand, misinsertion and mispair extension ratios obtained with RTs from porcine 
endogenous retrovirus were roughly similar to those obtained with MLV RT [107].  
The fidelity of yeast LTR retrotransposon Ty1 RT was found to be comparable to that of AMV RT 
in gel-based fidelity assays [108], in agreement with error rate estimates of 10
-5 misincorporations per 
nucleotide reported for the retrotransposed group II intron of Lactococcus lactis L1.LtrB [109]. On the 
other hand, it has been demonstrated that the RT of the LTR retrotransposon Tf1 of 
Schizosaccharomyces pombe shows a strong tendency to add non-templated nucleotides to the 3´-end 
of the nascent DNA, particularly in the presence of Mn
2+ [110]. Under these conditions, Tf1 RT 
showed marked infidelity, although in the presence of Mg
2+, nucleotide misincorporation levels were 
reduced in comparison with those obtained with the HIV-1 RT [110]. 
5. Structural Determinants of HIV-1 RT Fidelity 
The HIV-1 RT is an important target for antiretroviral therapy [reviewed in Refs. 111,112]. During 
the last twenty years, many studies have been published describing the role of different amino acids in 
the acquisition of resistance to antiretroviral drugs, as well as the effects of mutations on nucleotide 
specificity.  
The HIV-1 RT is a heterodimeric enzyme composed of two subunits of 66 and 51 kDa (p66 and 
p51, respectively), with subdomains termed ‘fingers’, ‘palm’, ‘thumb’ and ‘connection’ in both 
subunits and an RNase H domain in the larger subunit only [113,114]. As in other DNA polymerases 
fingers, palm and thumb subdomains of p66 form a large nucleic acid-binding cleft that extends into 
the connection subdomain and the RNase H domain. The bottom of the cleft is formed by the palm 
subdomain, which harbors the catalytic residues (Asp110, Asp185 and Asp186) that coordinate with 
two divalent ions. Binding of Mg
2+ in metal site A (catalytic site) is required to obtain an RT which is 
catalytically competent for DNA polymerization [115], while binding of Mg
2+ in site B is required for 
coordination with the triphosphate moiety and facilitates pyrophosphate dissociation [116]. Several 
residues in the vicinity of the catalytic triad, such as Lys65, Arg72, Asp113, Ala114, Tyr115 and 
Gln151 are involved in interactions with the incoming dNTP, while Leu74, Pro157, Phe160, Tyr183 
and Met184 could indirectly affect dNTP binding [114]. Mutational studies have shown that molecular 
determinants of nucleotide specificity and fidelity of DNA synthesis map within the HIV-1 RT p66 
subunit, mostly in the vicinity of the dNTP binding site. These analyses include measuring the effects 
of amino acid substitutions in the accuracy of DNA synthesis by using the M13mp2 lacZα forward 
mutation assay (Table 2), as well as detailed studies of the kinetics of nucleotide incorporation with 
different template-primers. Viruses 2009, 1                  
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Table 2. Accuracy of mutant HIV-1 RTs, as determined by using M13mp2 lacZα forward 
mutation assays. 
 
Mutation
a 
RT subunit 
composition
b 
Subdomain 
location 
Mutant frequency 
(x 10
-4)
c 
Fold- 
Change
d 
 
References 
M41L/T69SAG/AMs p66/p51
WT (HXB2)  fingers/palm  6.3 (97)  ↓ 15.3  [77] 
M41L/T69SSG/AMs p66/p51
WT (HXB2)  fingers/palm  5.9 (97)  ↓ 16.3  [77] 
F61A p66/p51
WT (HXB2)  fingers  8.3 (97)  ↓ 11.7  [75] 
A62V/T69SAG/AMs p66/p51
WT (HXB2)  fingers/palm  8.5 (97)  ↓ 11.4  [77] 
A62V/T69SSG/AMs p66/p51
WT (HXB2)  fingers/palm  19 (97)  ↓ 5.0  [77] 
A62V/T69SSS/AMs p66/p51
WT (HXB2)  fingers/palm  11 (97)  ↓ 8.8  [77] 
K65R  p66/p66 (BH10)  fingers  10.6 (86)  ↓ 8.1  [117] 
T69SAG p66/p51
WT (HXB2)  fingers  20 (97)  ↓ 4.8  [77] 
T69SSG p66/p51
WT (HXB2)  fingers  12 (97)  ↓ 7.5  [77] 
T69SSS p66/p51
WT (HXB2)  fingers  24 (97)  ↓ 4.0  [77] 
R72A  p66/p66 (HXB2)  fingers  340 (210)  ↑ 1.6  [118] 
L74V  p66/p66 (BH10)  fingers  50.5 (86)  ↓ 1.7  [117] 
 p66/p51
WT (BH10)    55 (192)  ↓ 3.5  [119] 
V75A  p66/p51 (BH10)  fingers  281 (206)  ↑ 1.4  [78] 
V75F  p66/p51 (BH10)  fingers  112 (206)  ↓ 1.8  [78] 
V75I  p66/p51 (BH10)  fingers  69.6 (206)  ↓ 3.0  [78] 
  p66/p51 (ESP49)    43.4 (83.1)  ↓ 1.9  [79] 
D76V  p66/p51 (BH10)  fingers  26 (232)  ↓ 8.8  [120] 
R78A  p66/p51 (BH10)  fingers  28 (250)  ↓ 8.9  [121] 
E89G p66/p51
WT (HXB2)  fingers  62.6 (86)  ↓ 1.4  [73] 
 p66/p51
WT (BH10)    96 (192)  ↓ 2.0  [119] 
E89G/M184V p66/p51
WT (HXB2)  fingers/palm  123 (86)  ↑ 1.4  [73] 
E89K p66/p51
WT (HXB2)  fingers  77 (86)  ↓ 1.2  [122] 
E89S p66/p51
WT (HXB2)  fingers  53 (86)  ↓ 1.6  [122] 
E89V p66/p51
WT (HXB2)  fingers  64 (86)  ↓ 1.3  [122] 
Y115A p66/p51
WT (BH10)  palm  763 (192)  ↑ 4.0  [119] 
V148I  p66/p66 (HXB2)  palm  30 (261)  ↓ 8.7  [76] 
  p66/p66 (SIV-CL8)    22 (178)  ↓ 8.1  [82] 
Q151M  p66/p66 (BH10)  palm  55 (64)  ↓ 1.2  [123] 
Q151M
COMPLEX  p66/p66 (BH10)  fingers/palm  31 (64)  ↓ 2.1  [123] 
Q151N  p66/p51 (BH10)  palm  20 (261)  ↓ 13.1  [124] 
K154A  p66/p51 (BH10)  palm  125 (261)  ↓ 2.1  [124] 
Y183F p66/p51
WT (BH10)  palm  303 (192)  ↑ 1.6  [119] 
M184I  p66/p51 (HXB2)  palm  24 (97)  ↓ 4.0  [74] 
M184V  p66/p51 (HXB2)  palm  55.3 (86)  ↓ 1.6  [73] 
 p66/p51
WT (BH10)    228 (192)  ↑ 1.2  [119] Viruses 2009, 1                  
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Table 2. Cont. 
 
Mutation
a 
RT subunit 
composition
b 
Subdomain 
location 
Mutant frequency 
(x 10
-4)
c 
Fold- 
Change
d 
 
References 
D256A  p66/p66 (HXB2)  thumb  240 (200)  ↑ 1.2  [125] 
Q258A  p66/p66 (HXB2)  thumb  390 (200)  ↑ 1.95  [125] 
K259A  p66/p66 (HXB2)  thumb  300 (200)  ↑ 1.5  [125] 
L260A  p66/p66 (HXB2)  thumb  230 (200)  ↑ 1.15  [125] 
G262A  p66/p66 (HXB2)  thumb  860 (210)  ↑ 4.1  [126] 
K263A  p66/p66 (HXB2)  thumb  290 (200)  ↑ 1.45  [125] 
W266A  p66/p66 (HXB2)  thumb  630 (210)  ↑ 3.0  [126] 
Q269A  p66/p66 (HXB2)  thumb  510 (200)  ↑ 2.55  [125] 
R277A  p66/p66 (HXB2)  thumb  140 (160)  ↓ 1.1  [127] 
Q278A  p66/p66 (HXB2)  thumb  190 (160)  ↑ 1.2  [127] 
L279A  p66/p66 (HXB2)  thumb  150 (160)  ↓ 1.1  [127] 
C280A  p66/p66 (HXB2)  thumb  300 (160)  ↑ 1.9  [127] 
K281A  p66/p66 (HXB2)  thumb  140 (160)  ↓ 1.1  [127] 
L282A  p66/p66 (HXB2)  thumb  120 (160)  ↓ 1.3  [127] 
R284A  p66/p66 (HXB2)  thumb  170 (160)  ↑ 1.1  [127] 
G285A  p66/p66 (HXB2)  thumb  160 (160)  =  [127] 
K287A  p66/p66 (HXB2)  thumb  120 (160)  ↓ 1.3  [127] 
a AMs stands for the additional mutations: L210W/R211K/L214F/T215Y; and Q151M
COMPLEX represents 
A62V/V75I/ F77L/F116Y/Q151M. 
b RTs used in these experiments were homodimers (p66/p66) or heterodimers (p66/p51). The WT superscript 
indicates that the corresponding subunit contains a wild-type sequence. The reference viral strain is shown 
between parentheses. All of them are HIV-1 group M subtype B strains except for ESP49 that derives from an 
HIV-1 group O isolate and CL8 that is an SIV strain. 
c The mutant frequencies indicated between parenthesis correspond to controls carried out with the 
corresponding wild-type RT. 
d ↑ and ↓ stand for increased and decreased mutant frequency (inaccuracy), respectively.  
 
Fidelity assays have demonstrated that the major structural determinants of the accuracy of DNA 
synthesis by HIV-1 RT are located in regions of the DNA polymerase domain, including: (i) dNTP 
binding site residues; (ii) residues that interact with the template strand; (iii) residues that interact with 
the primer strand; and (iv) minor groove binding track residues; as well as in the RNase H primer grip 
domain residues (Figure 3). 
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Figure 3. View of the nucleic acid binding cleft of HIV-1 RT showing the location of 
amino acids that influence fidelity of DNA synthesis (blue and orange CPK models). 
Ribbon diagrams are used for the representation of p66 (blue) and p51 (green). A stick 
representation is used for the template (red) and primer (magenta) strands of the 
DNA/DNA complex. The incoming dNTP is represented with a yellow CPK. Atomic 
coordinates were taken from Protein Data Bank file 1RTD [114]. 
 
 
5.1. dNTP binding site residues 
The side chains of Arg72 and Gln151 pack against the outer surface of the incoming dNTP, 
whereas the ribose ring of the nucleotide binds in a pocket defined by the side chains of Tyr115, 
Phe116 and Gln151. The side chain of Tyr-115 [as well as its equivalent residue in MLV RT 
(Phe155)] acts as a “steric gate”, preventing the incorporation of nucleotides with a 2´-hydroxyl group 
[128,129]. Although the substitution of Tyr115 by Phe renders a fully active RT [130,131], 
nonconservative substitutions at this position (e.g., Y115A, Y115S, Y115V, etc.) rendered RTs with 
reduced misinsertion and mispair extension fidelity in nucleotide incorporation assays carried out 
under steady-state conditions [129,130,132]. Mutant Y115A showed a 4-fold lower fidelity than the 
wild-type RT in lacZ-based forward mutation assays [119] (Table 2). In contrast, Y115F and Y115V 
showed less than 2-fold differences in their error rates, in similar assays carried out with a deoxyuracil-
containing DNA template [133]. Interestingly, the Y115A mutation increased by 2.3-fold the virus 
mutant frequencies in vivo, during one round of HIV-1 replication using the lacZ gene as a reporter 
gene [40]. A 2.8-fold increase in the mutation rate was also observed with a similar assay, when the Viruses 2009, 1                  
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F155W mutation was introduced in the RT-coding region of an MLV vector [134]. However, it should 
be noted that despite the strong evidence showing the role of Tyr115 in controlling fidelity of HIV-1 
RT, nonconservative substitutions at this position have a deleterious effect on the specific DNA 
polymerase activity of the RT and render nonviable HIV-1 when introduced in an infectious clone 
[135]. 
Amino acid substitutions affecting neighboring residues Ala114 (i.e., A114G, A114S) or Phe160 
(i.e., F160Y, F160W) did not seem to have a large impact in misinsertion and mispair extension 
fidelity [136,137]. However, the substitution of Asn for Gln151 rendered an RT with 13.1-fold 
decreased fidelity of DNA synthesis in M13mp2 lacZ forward mutation assays, in comparison with the 
wild-type enzyme [124]. In agreement with those observations, Q151N was found to decrease the viral 
mutation rate by 6-fold, in single-cycle replication assays [40]. Q151N RT was 120-fold less efficient 
at binding correct dNTP than wild-type RT [97]. However, mispair extension kinetics revealed that the 
higher accuracy of Q151N relates to its reduced ability to bind (Kd) and chemically incorporate (kpol) 
nucleotide substrate onto mismatched template-primers [76]. It has been proposed that Gln151 could 
be important for tight binding of incorrect dNTPs, thereby contributing to the low fidelity nature of 
HIV-1 RT. Nevertheless, other amino acid substitutions at this position such as Q151M do not seem to 
affect HIV-1 RT fidelity in a significant manner [123,138]. 
Met184 of HIV-1 RT is an important residue for the acquisition of resistance to antiretroviral drugs 
such as lamivudine and emtricitabine [reviewed in Ref. 111]. Drug resistance mutations such as 
M184V or M184I are relatively common in heavily-treated patients. Several studies have shown that 
M184V confers increased misinsertion and mispair extension fidelity in comparison with the wild-type 
RT [139-142]. However, this mutation had a relatively small impact on the mutant frequency, as 
determined in forward mutation assays [73,119]. In contrast, M184I produced a 4-fold increase in the 
RT’s accuracy [74] (Table 2). The M184I RT variant showed a reduction in frameshift mutations when 
compared with the wild-type enzyme, as well as an increase in the number of mutations occurring 
outside runs of nucleotides [74]. 
Lys65 and Arg72 stabilize dNTP binding through interactions with the γ- and α-phosphates of the 
incoming dNTP. The substitution of Arg for Lys65 emerges under antiretroviral treatment, particularly 
with tenofovir [for a review, see Ref. 111]. M13mp2 lacZ forward mutation assays showed that the 
K65R mutation confers 8-fold higher accuracy than the wild-type enzyme [117], a result that is 
consistent with the 3-fold reduction in the mutant frequency observed in single-cycle replication assays 
[40]. The comparison of the mutational spectra obtained with K65R and wild-type RTs revealed 
increased frameshift fidelity in the case of K65R RT. In addition, the number of occurrences of a 
particular type of error at the same site (i.e., hot spots) was reduced in reactions catalyzed by the 
mutant enzyme [117]. The substitution of Ala for Arg72 impairs polymerase activity by interfering 
with the pyrophosphate removal function of the RT [143,144]. Despite having similar fidelity in 
comparison with the wild-type enzyme, the mutant R72A RT was found to be highly error-prone for 
misincorporations opposite template T in the sequence context: 5´-CTGG, as demonstrated by kinetic 
experiments and forward mutation assays [118].  Viruses 2009, 1                  
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5.2. Residues that interact with the template strand 
Several mutations in the fingers subdomain of the RT that involve residues interacting with the  
5´ template overhang were shown to decrease the in vitro forward mutation frequency (Table 2). These 
amino acid substitutions include F61A [75], L74V [117,119], V75I [78,79], D76V [120], and R78A 
[121]. The largest effects on fidelity have been reported for mutant F61A. However, its mutational 
spectrum has not been reported. Phe61 together with Trp24 are required for accurate association of the 
HIV-1 RT with the template-primer [145]. Despite retaining significant DNA polymerase activity (as 
well as strand displacement activity) [75,146], Phe61 mutations were shown to cause a replication 
defect when introduced in viral clones [147]. In comparison with the wild-type RT, mutational spectra 
obtained with mutants L74V and V75I revealed only minor differences in the type of errors and their 
distribution across the lacZ reporter gene [79,117].  
Glu89 is of particular interest because it interacts with the sugar-phosphate backbone of the 
template strand around template position –2, and appears to be important for RT activity and drug 
resistance. Despite the fact that the E89G RT displayed increased fidelity of dNTP insertion and 
mispair extension; forward mutation assays failed to demonstrate a significant effect of this mutation 
in fidelity [73,119] (Table 2). However, the mutational spectra of E89G and E89G/M184V RTs 
revealed a frameshift hot spot that was not found with the wild-type enzyme [73]. Mutant RTs having 
Ala, Asp, Asn, Gly, Lys, Ser, Thr or Val, instead of Glu89 showed reduced –1 frameshifting and 
increased +1 frameshifting suggesting that Glu89 can influence slippage of both strands [122]. An 
association between –1 frameshifting and reduced dNTP incorporation rates was also observed. A salt 
bridge between Glu89 and Lys154 appears to facilitate –1 frameshifting. This observation is consistent 
with the 7.5 to 10-fold reduction in –1 frameshifting observed for mutants K154A and K154R [122]. 
The effects of RT mutations L74V, D76V, R78A and E89G on the retroviral mutation rates have 
been analyzed in single-cycle replication assays [40]. The largest effects were observed with R78A 
and D76V that caused 3.5- and 2.5-fold reductions in the observed mutant frequencies in comparison 
with the wild-type HIV-1 vector. Interestingly, the combination of D76V and R78A produced a further 
significant reduction in the average mutant frequencies (0.151 ± 0.006 versus 0.015 ± 0.005 mutants 
per cycle for the wild-type and the double-mutant D76V/R78A, respectively). 
5.3. Residues that interact with the primer strand 
The largest effects on fidelity have been reported for mutations affecting the primer grip region of 
p66 (i.e., residues 227-235 of the palm subdomain). RTs having Ala instead of Phe227, Trp229, 
Met230, Gly231 or Tyr232 were 40 to 76% less efficient than the wild-type enzyme in extending a 
mismatch in primer extension assays carried out with a mixture including all dNTPs [148]. On the 
other hand, single-cycle replication assays revealed that mutations F227A and W229A produced only a 
small decrease (<2-fold) in the mutant frequency, suggesting a relatively minor effect on fidelity [40]. 
However, we have previously shown that the primer grip mutation M230I increases the rate of T:G 
misinsertion by 16-fold in assays carried out under steady-state conditions [149]. M230I emerges as a 
compensatory mutation for the dNTP binding defect shown by an HIV-1 RT bearing Trp at position 
115 [135]. A genetic screen based on the blue-white β-galactosidase complementation assay designed 
to detect GA mutations arising during RNA-dependent DNA synthesis revealed that mutant RTs Viruses 2009, 1                  
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bearing mutations M230L or M230I were 20 to 70 times less faithful than the wild-type RT in the 
presence of low [dCTP]/[dTTP] ratios, but showed similar fidelity in assays carried out with equimolar 
concentrations of each nucleotide [150]. 
5.4. Minor groove binding track residues 
DNA binding track interactions occur in the minor groove where the DNA undergoes a structural 
transition from A-like to B-form DNA [114,151]. Ile94, Gln258, Gly262, Trp266 and Gln269 are 
considered to be of potential importance for binding to duplex template-primer in this region. Alanine-
scanning mutagenesis of residues 253-271 (α-helix H) and 277-287 (α-helix I) have shown that these 
structures have a role in template-primer binding and processivity. Amino acid substitutions involving 
α-helix H residues Gly262 and Trp266 were shown to increase the error rate of HIV-1 RT [125,126]. 
Mutant enzymes containing either G262A or W266A had decreased template affinity, processivity, 
and frameshift fidelity, and were able to synthesize a small amount of full-length DNA product, in 
comparison with the wild-type RT. Both mutations appear to be deleterious for viral replication [40]. 
5.5. RNase H primer grip domain residues 
The RNase H primer grip domain was identified as a structural element of HIV-1 RT that is 
involved in the control of RNase H cleavage specificity [152]. In HIV-1 RT, the RNase H primer grip 
includes Tyr501, a residue that interacts with the DNA primer and facilitates its proper positioning in 
relation to the RNase H active site [153]. Tyr501 of HIV-1 RT is part of the DSXY conserved motif 
found in all retroviral RNase H domains, except RSV RT. The equivalent residue of MLV RT is 
Tyr586. The substitution of Phe for Tyr586 in MLV RT increased the in vivo mutation rate by 
approximately 5-fold [59]. DNA-sequencing analysis indicated that the Y586F mutation increased the 
frequency of base substitution mutations 17-fold within adenine-thymine tracts (AAAA, TTTT, or 
AATT sequences), which are known to induce bends in DNA. Another substitution at the equivalent 
position in HIV-1 (Y501W) produced a 2.7-fold increase in the mutant frequency obtained in one 
round of HIV-1 replication assays, using lacZ as a reporter gene [40]. In contrast, the RNase H primer 
mutation (I505A) had a non-significant effect on fidelity in this type of assays [40].  
More recently, Mbisa et al. [154] showed that significant increases (2.1- to 3.8-fold) in the viral 
mutation rates could be obtained by introducing mutations S557A, A558V and Q559L in the   
RT-coding region of an MLV vector. These mutations as well as Y586F increased the frequency of 
deletions between the primer binding site (PBS) and sequences downstream of the PBS, and support a 
relevant role for the RNase H primer grip in controlling fidelity of DNA synthesis in vivo. 
6. Biological Consequences of Increasing or Decreasing Fidelity: Questions and Perspectives 
The publication of evidence suggesting that a mutation emerging under antiretroviral therapy 
(M184V) increased the fidelity of HIV replication [139] triggered hot debate on whether antiretroviral 
therapy could delay the appearance of drug-resistant viruses. Earlier clinical studies revealed that 
M184V had a minor impact in the evolutionary potential of the virus [155,156], although there is at 
least one report showing the delay in the development of resistance to amprenavir and efavirenz when Viruses 2009, 1                  
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M184V is present [157]. Nevertheless, in vitro studies suggest that the effects of M184V in fidelity are 
modest. Theoretical models considering the viral replication rate, fitness and fidelity of the virally 
encoded RT suggested that, in order for increases in fidelity to make an impact on the rate at which a 
subsequent variant appears, increases in polymerase fidelity should be very large [3,158]. Drug-
resistant HIV-1 RTs such as M41L/T69SSS/L210W/R211K/L214F/T215Y and related enzymes, 
appear to show the largest increase in accuracy [77]. However, their effects on viral evolution have not 
been studied in detail.  
On the other hand, an increase of the error rate above a critical threshold could lead to the loss of 
genetic information in a process termed “error catastrophe”. This strategy, termed lethal mutagenesis, 
is based on the concept that only a modest increase in the viral mutation rate is needed to render the 
virus non-viable [159-161]. The validity of lethal mutagenesis is supported by experimental evidence 
showing an inverse correlation between mutation rate and infectivity of several RNA viruses, 
including retroviruses [162-165]. Nucleoside analogues (e.g., 5-azacytidine, 5-hydroxydeoxycytidine, 
etc.) have been shown to effectively increase mutation rates of various retroviruses, including SNV, 
MLV, FIV and HIV-1 [159,166-169]. In most cases, these effects are the result of variations in 
intracellular dNTP pools that could affect virus titers, as well as the rate and spectrum of retroviral 
mutations [170]. It should be noted that variations in the dNTP pools may not affect all retroviruses in 
the same manner (e.g., MLV RT shows a higher affinity for dNTPs than HIV-1 RT [98]). Interestingly, 
certain drugs could alter dNTP pools and cause mutational bias. Thus, it has been reported that the 
administration of 2´-deoxycytidine and tetrahydrouridine can reverse the characteristic GA 
mutational bias found in HIV-1 [171].  
In summary, available data suggest that the control of the viral mutation rate could be a viable 
antiretroviral strategy. Still more work needs to be done in order to understand the molecular 
mechanisms involved in controlling fidelity not only at a molecular level (i.e., intrinsic RT fidelity), 
but also related to the identification of intracellular factors that modulate the viral mutation rate   
(e.g., cellular polymerases and their regulators, and variations in the nucleotide pools). One of the 
defying future challenges in this area of research would be the design and development of mutagenic 
nucleoside analogues devoid of potential toxicity and carcinogenicity, and showing higher specificity 
for the retroviral RTs. 
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